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We have examined the relationship between coreceptor utilization and sensitivity to neutralization in a
primary isolate of human immunodeficiency virus type 1 and its T-cell line-adapted (TCLA) derivative. We
determined that adaptation of the primary-isolate (PI) virus 168P results in the loss of the unique capacity of
PI viruses to utilize the CCR5 coreceptor and in the acquisition by the TCLA 168C virus of sensitivity to
neutralization by V3-directed monoclonal antibodies (MAbs). In experiments wherein infection by 168P is
directed via either the CCR5 or the CXCR4 pathway, we demonstrate that the virus, as well as pseudotyped
virions bearing a molecularly cloned 168P envelope protein, remains refractory to neutralization by MAbs
257-D, 268-D, and 50.1 regardless of the coreceptor utilized. This study suggests that coreceptor utilization is
not a primary determinant of differential neutralization sensitivity in PI and TCLA viruses.
Although CD4 had long been recognized as the cellular
receptor to which the human immunodeficiency virus type 1
(HIV) envelope protein binds (9, 21, 22), it had also been
recognized that expression of CD4 alone is insufficient to ren-
der nonhuman cells susceptible to HIV infection (4, 5, 22).
Similarly, different HIV isolates display different abilities to
infect CD4-positive human macrophages, T lymphocytes, and
established T-cell lines (31, 32, 35), suggesting that additional
molecules may be responsible for cell tropism specificity. Dur-
ing the past year, cellular molecules that act in conjunction
with CD4 have been identified as required cofactors for HIV
envelope protein-mediated binding and entry (1, 6, 10–12, 14).
These HIV coreceptors are members of the superfamily of
seven-transmembrane segment G-protein-coupled receptors
and act primarily as cellular receptors for chemokines.
The discovery of cellular coreceptors for HIV has provided
new perspectives for understanding these early events in HIV
infection (see review in reference 2). Thus, phenotypically dis-
tinct isolates of HIV utilize as coreceptors different chemokine
receptor molecules. Although all primary isolates of HIV in-
fect primary T lymphocytes, some also infect cells of the mac-
rophage lineage (31, 32). These monocyteropic isolates utilize
the CCR5 chemokine receptor, whose natural ligands include
the chemokines RANTES, MIP-1a, and MIP-1b (1, 6, 10–12).
Monocytropic isolates do not induce syncytia in primary lym-
phocyte culture and do not infect established T-cell lines (31).
During the late course of HIV infection, syncytium-inducing
(SI) primary viruses often arise from the population of mono-
cytropic viruses (31, 32). These SI primary isolates no longer
infect macrophages, and they utilize both CCR5 and another
chemokine receptor, CXCR4 (7, 33, 38). CXCR4, whose nat-
ural chemokine ligand is SDF-1 (3, 27), was originally identi-
fied by Feng et al. as the cofactor used by laboratory-adapted
viruses (14). In fact, the common laboratory viruses (IIIb/LAI,
LAV, and RF) are unable to utilize CCR5 coreceptor (1, 6,
10–12), presumably reflecting the lack of CCR5 expression in
most established T-cell lines (1, 13). Although some primary
isolates utilize additional chemokine receptor molecules, no-
tably CCR3 and CCR2b (6, 11, 18), the relationship between
these coreceptors and viral phenotypes is less clear. The ability
to utilize CCR5 coreceptor, however, is unique to primary-
isolate (PI) viruses.
Paralleling these differences in coreceptor utilization and
cell tropism are differences in sensitivity to virus neutralization.
Although laboratory-adapted isolates of HIV can be potently
neutralized by sera elicited by recombinant gp120 (rgp120)
protein, primary isolates are largely refractory to neutraliza-
tion by rgp120 vaccine sera (23, 37). Similarly, PI viruses are
significantly more resistant than T-cell line-adapted (TCLA)
viruses to neutralization by gp120-directed monoclonal anti-
bodies (MAbs) (25, 37) and to inhibition by soluble forms of
CD4 (8). We and others have demonstrated that neutralization
sensitivity develops concomitantly with adaptation of primary
isolates to persistent growth in established T-cell lines (24, 37).
By studying pedigreed PI and TCLA viruses (168P and 168C,
respectively), we have shown that adaptation renders the
TCLA virus sensitive not only to rgp120 vaccine sera and CD4
immunoadhesin but also to MAbs directed to the V3 loop of
gp120 (37). However, the basis for this increase in neutraliza-
tion sensitivity remains unclear.
In this report, we explore the relationship between neutral-
ization sensitivity and coreceptor utilization, especially with
regard to changes that accompany adaptation. We examined
neutralization sensitivity of the well-characterized SI primary
isolate 168P under experimental conditions where infection
can be directed via either the CXCR4 or the CCR5 pathway.
The pedigreed TCLA derivative 168C utilizes only CXCR4
and was sensitive to neutralization by the panel of V3-directed
MAbs used in these assays. However, the primary isolate 168P
remained refractory to neutralization regardless of coreceptor
pathway taken. Our findings suggest that envelope protein
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structure, and not coreceptor utilization, is the primary deter-
minant of differential neutralization sensitivity in PI and TCLA
viruses.
Coreceptor utilization by pedigreed PI and TCLA viruses.
Cross-sectional surveys of coreceptor use have shown that pri-
mary SI isolates generally utilize CXCR4 and CCR5 corecep-
tors, whereas unrelated laboratory-adapted isolates utilize only
CXCR4 (1, 6, 7, 10–12, 14, 33, 38). We wished to confirm this
trend in a longitudinal study of adaptation. We previously
described the adaptation of the SI primary isolate 168P to
persistent growth in the FDA/H9 T-cell line and the concom-
itant development of neutralization sensitivity in the resulting
TCLA virus 168C (37). In the present study, the ability of these
pedigreed viruses to utilize specific coreceptors was tested by
infection of U87 human glioma cell lines expressing CD4
(U87-CD4) and the specific coreceptor (19).
For this assay, virus stocks were prepared from cell culture
supernatants of phytohemagglutinin (PHA)-stimulated periph-
eral blood lymphocytes (PBLs) (168P) or FDA/H9 cells (168C)
and standardized to yield a submaximal number of foci of
infection on U87-CD4-CXCR4 cells (approximately 100 to 200
foci/96-well microplate culture). To confirm coreceptor speci-
ficity, in some assays CCR5 chemokines (each at 500 ng/ml)
were added to cells 1 h prior to infection. After 2 days of
incubation, cell monolayers were fixed with methanol-acetone
and immunochemically stained with HIV immunoglobulin
(HIVIG) (29), anti-human ABC kit (Biomeda Corp.), and
diaminobenzidine substrate.
Figure 1 confirms the ability of the SI 168P virus to utilize
both CXCR4 and CCR5 and the subsequent loss of this latter
specificity in the 168C TCLA virus. Infection was dependent
on coreceptor expression, and both PI and TCLA viruses could
also utilize CCR3 (data not presented).
In keeping with the determined coreceptor specificity, infec-
tion could be blocked by addition of coreceptor-specific li-
gands. Thus, 168P virus infection of CCR5-expressing cells was
blocked by the CCR5-specific ligands RANTES, MIP-1a, and
MIP-1b (1, 6, 10–12) (Fig. 1). Similarly, infection of CXCR4-
expressing U87-CD4 cells by either virus could be blocked by
the CXCR4-specific chemokine ligand SDF-1 (3, 27) (data not
presented).
Coreceptor pathway and neutralization sensitivity. In pre-
vious work, we demonstrated that the PI 168P virus is refrac-
tory to neutralization by HIV MN gp120 vaccine sera and by
several well-characterized V3-directed murine MAbs which
strongly neutralize infectivity of the TCLA 168C virus (37). In
the present study, we extended the panel of MAbs to include
two V3-directed human MAbs, 257-D and 268-D (17). These
well-characterized human MAbs recognize core epitopes at the
crown of the V3 loop of gp120 (KRIHI and HIGPGR, respec-
tively), linear sequences known to be present in both 168P and
168C envelope proteins (37). These epitope predictions were
confirmed by gp120 capture enzyme-linked immunosorbent
assay (ELISA) (26) which demonstrated equal binding to en-
velope protein in detergent-solubilized 168P and 168C virions
(data not presented). Sensitivity to neutralization by these hu-
man MAbs was determined in a standard assay using PHA-
activated PBLs (37). MAbs 257-D and 268-D were found to
potently neutralize 168C but fail to neutralize 168P (Fig. 2).
This pattern of neutralization sensitivity is similar to that pre-
viously described for the V3-directed murine MAb 50.1 (30, 36,
37).
To examine whether sensitivity to neutralization was af-
FIG. 1. Coreceptor utilization by pedigreed PI and TCLA 168 viruses. U87-
CD4 cell lines expressing CXCR4 (■) or CCR5 (u) were used to define the
ability of 168P and 168C viruses to utilize the respective coreceptor. CCR5
utilization was further tested by the addition to U87-CD4-CCR5 cells of CCR5-
specific chemokines (RANTES, MIP-1a, and MIP-1b; R&D Systems) (M). For
details, see text. p, no foci were observed.
FIG. 2. Neutralization sensitivity of 168 viruses in PBL culture. Virus neutralization assays in PHA-stimulated PBL culture were performed as previously described
(37). 168P (E, F) and 168C (M, ■) virus stocks were standardized to yield submaximal extents of virus spread during the 5-day infection. CCR5-specific chemokines
(F, ■) were added as described for Fig. 1. The V3-directed MAbs are indicated. p24 antigen was determined by p24 antigen capture ELISA (SAIC Frederick) and
was normalized to infected cell control values (168P, 190 ng/ml [170 ng/ml with chemokines]; 168C, 36 ng/ml [33 ng/ml with chemokines]).
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fected by the coreceptor pathway utilized in infection of PBLs,
we used inhibitory concentrations of CCR5-specific chemokine
ligands RANTES, MIP-1a, and MIP-1b in order to restrict
infection to the CXCR4 pathway. Addition of these chemo-
kines to the PBL cultures did not affect virus growth, nor did it
affect sensitivity to neutralization by the V3-directed human
MAbs (Fig. 2). To the extent that CCR5 blockade was com-
plete, these results suggest that the simple availability of the
CCR5 pathway is not a factor in the resistance of PI viruses to
neutralization.
To strengthen this conclusion, we examined neutralization
sensitivity in human U87-CD4 cell lines expressing only
CXCR4 or CCR5. Using this method, we confirmed that the SI
168P virus remained refractory to neutralization by human
MAbs 257-D and 268-D as well as by the murine MAb 50.1,
regardless of whether infection occurred via CXCR4 or CCR5
(Fig. 3). These results suggest that availability of the CCR5
pathway is not a primary determinant for the resistance of PI
viruses to neutralization. The TCLA 168C virus utilized
CXCR4 only and was sensitive to neutralization.
Molecularly cloned PI and TCLA envelope genes. To under-
stand better the changes that accompany adaptation and those
that determine coreceptor utilization and neutralization sensi-
tivity, we molecularly cloned the envelope genes of the 168P
and 168C viruses. High-fidelity XL PCR (rTth and Vent DNA
polymerases; PE Applied Biosystems) and primers envA and
envN (15) were used to amplify a 3.1-kb region of proviral
DNA encoding the rev and envelope genes. PCR products
were isolated by unidirectional T/A cloning in the eucaryotic
expression vector pCR3.1-Uni (Invitrogen). Expression in
pCR3.1-Uni is driven by the cytomegalovirus immediate-early
promoter. Multiple clones were isolated from each virus, and
transient transfection studies in COS-7 cells confirmed the
surface expression and fusion competence of all clones tested
(data not presented).
DNA sequence analysis demonstrated that all 168C molec-
ular clones analyzed encoded the three adaptation-associated
amino acid changes previously identified by PCR sequencing
of the 168C virus population (V2, I166R; C2, I282N; and V3,
G318R) (37). Two molecular clones of each 168P and 168C
envelope were subjected to complete DNA sequence analysis
(GenBank accession no. AF035532 to AF035534). Molecular
clones 168C23 and 168C60 were identical throughout the en-
velope gene. Molecular clones 168P5 and 168P23 differed from
each other and from the previously determined sequence at
four to five positions distinct from those associated with adap-
tation. These scattered changes within the primary virus quasi-
species are considered inconsequential at the present level of
analysis; the significance of the three adaptation-associated
changes is under separate investigation.
Functional analysis of these molecularly cloned envelope
genes was performed by incorporation of the molecularly
cloned envelope protein into pseudotyped HIV virions. We
used an envelope-defective provirus derived from the molec-
ularly cloned NL4-3 provirus (kindly provided by I. S. Y. Chen,
University of California, Los Angeles). The pNLthyDBgl pro-
virus (28) contains a BglII-BglII deletion within the envelope
gene and a substitution of the viral nef gene with a cDNA
encoding the murine Thy1.2 cell surface protein. The simian
virus 40 ori was subsequently introduced into the plasmid to
generate pSVNLthyDBgl (27a). Cotransfection of COS-7 cells
(16, 20) with pSVNLthyDBgl provirus and the envelope expres-
sion plasmid resulted in the production of pseudotyped HIV
virions. Culture supernatants were harvested 3 days posttrans-
fection, filtered, and used to infect U87-CD4 cell lines express-
ing coreceptor. Cells infected by virions bearing the comple-
menting envelope protein were identified by immunostaining
for murine Thy1.2 or HIV proteins.
As anticipated, the molecularly cloned envelope proteins
recapitulated the coreceptor specificity of the parental virus
population (see the legend to Fig. 4). Pseudotyped virions
containing 168C60 were able to infect only U87-CD4 cells
expressing CXCR4, while virions containing 168P23 envelope
were able to infect U87-CD4 cells expressing either CCR5 or
CXCR4. Thus, the viral envelope protein appears to be the
major, if not sole, determinant of viral coreceptor use. These
findings also indicate that dual coreceptor use is a direct prop-
erty of the envelope protein complex and not a result of a
mixture of distinct envelope proteins in the SI virus population.
This conclusion is corroborated by the failure of CCR5-specific
chemokine ligands to diminish 168P virus infection in PBL
culture (Fig. 2).
Finally, we wished to determine the neutralization sensitivity
of pseudotyped virions containing the molecularly cloned
168P23 and 168C60 envelope proteins and to confirm that
coreceptor pathway is not a primary determinant of neutral-
ization sensitivity. We found that infection of U87-CD4-
CXCR4 cells by pseudotyped virions containing 168C60 enve-
lope protein was sensitive to neutralization by MAbs 257-D,
268-D, and 50.1 at concentrations comparable to those deter-
mined in assays using 168C virus (Fig. 4). Pseudotyped virions
containing 168P23 envelope protein remained refractory to
neutralization by all three V3-directed MAbs, regardless of the
coreceptor expressed by the U87-CD4 cell line.
FIG. 3. Neutralization sensitivity of 168 viruses in U87-CD4 cell lines expressing CCR5 or CXCR4 coreceptor. 168P (E, F) and 168C (■) viruses were used to infect
U87-CD4 cell lines expressing CXCR4 (F, ■) or CCR5 (E) as described for Fig. 1. The V3-directed MAbs were incubated with virus for 1 h prior to infection.
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In summary, we examined the relationship between corecep-
tor utilization and sensitivity to neutralization by V3-directed
MAbs. The observed dichotomy in the sensitivity to neutral-
ization of PI and TCLA viruses had suggested a discrete dif-
ference between these viruses, and we tested one hypothesis:
that PI viruses are refractory to neutralization as a result of
their unique ability to utilize the CCR5 coreceptor. We exam-
ined neutralization sensitivity of a well-characterized SI pri-
mary isolate under experimental conditions wherein the virus
was forced to utilize either CCR5 or CXCR4 for infection. We
showed that coreceptor pathway is not a direct determinant of
neutralization sensitivity. The primary virus envelope protein
remained refractory to neutralization by V3-directed MAbs
regardless of the coreceptor pathway utilized. Similarly, core-
ceptor utilization did not affect neutralization sensitivity by
soluble CD4 (34) or HIVIG (data not presented).
In discarding the otherwise attractive hypothesis that PI
viruses escape neutralization through their unique ability to
utilize CCR5, we are left to consider the as yet undefined
structural differences between the envelope protein complex of
PI and TCLA viruses. Several studies have suggested that
critical determinants in the envelope protein of PI viruses are
less accessible than those of TCLA viruses and that it is this
differential access that determines neutralization sensitivity
(reviewed in reference 25). By contrast, our studies have indi-
cated similar binding of V3-directed MAbs to PBLs infected
with neutralization-resistant isolate 168P or neutralization-
sensitive isolate 168C (37). Thus, the basis for the differential
neutralization sensitivity of PI and TCLA viruses remains un-
resolved.
Our present studies also do not address whether changes in
coreceptor utilization and/or neutralization sensitivity are nec-
essarily linked as a consequence of adaptation. The analysis of
independently derived PI and TCLA viruses may allow further
separation of these viral phenotypes. Subsequent dissection of
the amino acid changes that distinguish pedigreed PI and
TCLA envelope proteins will help to define the structural
bases underlying the changes that accompany adaptation.
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